

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35.U.S.C. 371

EXPRESS MAIL LABEL No
EJ 339 571 850 US

DATE
April 18, 2000

ATTORNEY'S DOCKET NO
A33131-PCT-USA 67858.0101

U.S. APPLICATION NO
To be assigned 09/529759

INTERNATIONAL APPLICATION NO
PCT/FR98/02244

INTERNATIONAL FILING DATE
October 20, 1998

PRIORITY DATE CLAIMED
October 20, 1997

TITLE OF INVENTION

Documentation Means for Repertoires of NKR Immunoreceptors and/or Acitvatory or Non-Inhibitory Immunoreceptor Counterparts of NKR Immunoreceptors

APPLICANT(S) FOR DO/EO/US


Inserm

Applicant herewith submits to the United States Designated /Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

INTERNATIONAL APPLICATION NO PCT/FR98/02244 09/529759		INTERNATIONAL FILING DATE October 20, 1998		PRIORITY DATE CLAIMED October 20, 1997	
17. [] The following fees are submitted:				CALCULATIONS PTO USE ONLY	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) Nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO (1.492(a)(3)) \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO (1.492(a)(5)) \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO(1.492(a)(2)) \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) (1.492(a)(1)) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).				\$	
Claims	Number Filed	Number Extra	Rate	\$	
Total Claims	23-20=	3	X \$ 18.00	\$ 54.00	
Independent Claims	5-3=	2	X \$ 78.00	\$ 156.00	
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$ 260.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 1310.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 1310.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$	
TOTAL NATIONAL FEE =				\$ 1310.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+ \$ 40.00	
TOTAL FEES ENCLOSED =				\$ 1350.00	
				Amt. refunded	\$
				charged	\$ 1350.00
a. [✓] A check in the amount of \$ 1350.00 to cover the above fees is enclosed. b. [] Please charge our Deposit Account No. <u>02-4377</u> in amount of \$___ to cover the above fees. A copy of this sheet is enclosed. c. [✓] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4377</u> . A copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
BAKER BOTTS L.L.P. 30 Rockefeller Plaza New York, New York 10112-4498			John D. Murnane Registration No. 29,836		
			 Carmella L. Stephens Registration No. 41,328		

2/parr

WO 99/20794

PCT/FR98/02244

Means of documenting repertoires of NKR immunoreceptors
and/or of activatory or non-inhibitory immunoreceptor
counterparts of NKR immunoreceptors

5 The present invention relates to means which
make it possible to document the repertoires, in an
individual or an animal, of NKR (*Natural Killer*
Receptor) immunoreceptors of the immunoglobulin type or
of the lectin type, and of activatory, or at the very
10 least non-inhibitory, immunoreceptor counterparts of
NKR immunoreceptors. It also relates to their
biological applications.

 The immune functions in humans or animals are
defined by several categories of highly diversified
15 molecules, such as in particular the ABO blood group
system, the family of MHC (*Major Histocompatibility*
Complex, called, in humans, *HLA - Human Leukocyte*
Antigen - system) molecules, the family of receptors
for the T lymphocyte antigen (TCR) and B lymphocyte
20 antigen (BCR). All the molecules which an adult
individual expresses, or is capable of expressing, for
each of these different families constitute, with the
exception of identical twins, an evolutive repertoire
which is specific to them and which is involved in self
25 or non-self recognition.

 Other main repertoires have been more recently
identified. They are the immunoglobulin-type NKR
receptor repertoire and the lectin-type NKR receptor
repertoire. The immunoglobulin-type NKR receptors
30 comprise the KIR receptors (*Killer cell Inhibitory*
Receptors) such as in particular the p58.1, p58.2,
p70.INH and p140.INH receptors. The lectin-type NKR
receptors comprise the inhibitory NKG2 receptors such
as in particular the NKG2A and NKG2B receptors. All
35 these NKR receptors have an inhibitory function.
Receptors which are highly homologous to them, in
particular at the extracytoplasmic level, however
fulfil activatory, or at the very least non-inhibitory,

functions: they are the KAR receptors (*Killer cell
Activatory Receptors*) which are homologous to the KIR
receptors, and NKG2C, NKG2D, NKG2E and NKG2F receptors
which are homologous to the NKG2A and NKG2B receptors.

5 The activatory, or at the very least non-inhibitory,
receptor counterparts of the inhibitory NKR receptors
are hereinafter designated, for the sake of
convenience, NKR counterparts.

10 The NKR receptors and the NKR receptor
counterparts are naturally expressed by the NK cells
and by subpopulations of T cells. Several of these
receptors may be expressed by the same cell. All these
receptors, whether they are inhibitory (*i.e.* NKR) or
activatory or non-inhibitory (*i.e.* NKR counterparts),
15 have in common the fact that they have as ligand
molecules which are not antigen-derived: the ligands
for the NKR receptors and for the NKR receptor
counterparts are MHC class I molecules.

20 The recognition of its ligand by an NKR
receptor triggers the transduction, to the cell, of a
message intended to inhibit its activity, *e.g.*
reduction or termination of cytolysis, of secretion of
cytokines, whereas the recognition of its ligand by an
NKR receptor counterpart induces therein an activatory,
25 or at the very least non-inhibitory, message. The
result of the NKR receptors and NKR receptor
counterparts thus activated by their ligands is a
signal, which is negative or positive overall, for
activation of the NK and/or T cells expressing them.

30 The NKR receptors and their counterparts thus
participate in the positive or negative control of the
allogenic reactions of a given immune system with
respect to what it then considers as non-self for
example, cancer cells or infected cells, or
35 alternatively allo- or xeno-genic graft or transplant
cells.

The NKR receptors and their counterparts indeed
participate in the reactions between host and graft
during a grafting (or transplantation) of cells, tissue

or organ which exhibit(s) a degree of antigenic incompatibility with the host. The involvement of NKR receptors and their counterparts in the tolerance towards incompatible grafts, and in the selective
5 effect of lysis of malignant cells sometimes observed after a bone marrow graft, or GVL (*Graft Versus Leukemia*) effect, has indeed been demonstrated *in vivo* (cf. Cambiaggi et al. 1997, Proc. Natl. Acad. Sci. USA, vol. 94, p. 8088-8092; Albi et al. 1996, Blood, vol.
10 87, No. 9, p. 3993-4000).

However, the means which can currently be used in a medical context do not make it possible to document all the repertoires of a patient, of an organ, of a tissue or of cells.

15 Accordingly, only the compatibility of the HLA-A, HLA-B and HLA-DR molecules of the donor and of the recipient is currently checked prior to an allo- or xeno-genic graft or transplant. These compatibility criteria do not however appear to be satisfactory.
20 Immunosuppressive treatments (for example based on cyclosporin) should supplement these graft or transplant procedures so as to inhibit the patient's immune system. Such treatments have high risks for the patient who is then likely to develop opportunistic
25 infections. These immunosuppressive treatments must furthermore be maintained at a certain level for several years, and the patient then has to withstand the damaging effects of the medicaments. Finally, the success of such graft or transplant procedures remains
30 uncertain. Indeed, graft rejections on the part of the recipient, or alternatively, in the case of grafts comprising immunocompetent cells, graft-versus-host reactions (GVH effect) are nevertheless observed. Such rejection or GVH reactions generally lead to very
35 severe lesions; currently, they cannot however be completely avoided, and therefore prevented.

Unexpected beneficial effects of allogenic grafts have, moreover, sometimes been observed: allogenic grafts of bone marrow in aplastic leukaemia

patients have sometimes led to a therapeutic antitumour effect through lysis of the malignant cells of the recipient and preservation of their healthy cells. This selective therapeutic effect, in which the NK and T cells are involved, is designated GVL (*Graft Versus Leukemia*). Potentially, a grafting (or a transplantation) of haematopoietic tissue in general, and of bone marrow in particular, can lead to a therapeutic effect in the context of haematological malignancies such as a leukaemia, through selective lysis of those cells from the recipient which no longer have the histocompatibility antigens presented by healthy cells. The means currently available to the medical setting do not make it possible, however, to predict if the organ or the tissue considered will exert a selective GVL effect for the recipient considered. Although known, the selective GVL effect cannot therefore be currently exploited in the context of an anticancer therapy.

The means currently developed in the context of experimental research studies in order to document the different repertoires of human or animal cells in fact do not make it possible to precisely document the repertoire of NKR receptors and of NKR receptor counterparts: the precise identity of each NKR receptor or NKR counterpart cannot be determined. Because of the strong homology, in particular at the extracytoplasmic level, between an NKR receptor and an NKR receptor counterpart (e.g. up to 96% homology between KIR and KAR), the use of antibodies indeed often do not make it possible to discriminate between NKRs which are inhibitory and their counterparts with activatory, or at the very least non-inhibitory, functions. The oligonucleotide primers which are currently available, for their part, do not allow the use of a polymerase chain reaction capable of discriminating between, for example, an NKR p58.1 and an NKR p58.2, or between an NKR p70.INH and an NKR p140.INH. Finally, to accurately document the repertoire of NKR immunoreceptors and of

their counterparts, use must currently be made, after a step of purifying the desired receptors (e.g. by FACScan), of a nucleotide sequencing step. The documenting of the NKR/NKR counterpart repertoire
5 cannot therefore be currently performed routinely in a medical-type context. The level of stimulation and inhibition of the programmes of activation of the NK and T cells, and therefore the potential of an individual to be resistant to the development of
10 microbial or parasitic infections, of autoimmune diseases, or alternatively of malignant cells, cannot therefore be measured. The result of this lack of suitable means for documenting NKR/NKR counterpart repertoires is also that the selective GVL-type effects
15 cannot be used in therapy, and that the GVH or rejection reactions during allo- or xeno-genic grafts or transplants cannot be completely avoided.

The present invention therefore provides means which make it possible to document, for a given
20 biological sample, the repertoires of NKR immunoreceptors and of activatory or at the very least non-inhibitory immunoreceptor counterparts of NKR receptors. These means make it possible in particular to easily distinguish between an NKR receptor and its
25 activatory or non-inhibitory counterpart, as well as to distinguish between various NKR receptors, or between various NKR counterparts. It also relates to the biological, and in particular medical and veterinary, applications of these means. One of the essential
30 aspects according to the invention consists in considering all the NKR immunoreceptors and NKR counterparts as a repertoire, that is to say as a coherent set, forming a unit with respect to a type of activity, in this case, in a particularly advantageous
35 manner, the control of lymphocyte activation in humans or animals from which the said biological sample is derived (negative control for the NKR receptor repertoire, positive control for the NKR counterpart receptor). The invention provides, for the first time,

means which make it possible to document, routinely in a medical or veterinary context, NKR and/or NKR counterpart repertoires, so as to be able to rapidly and effectively analyse physiological and pathological situations linked to these repertoires.

The means according to the invention have in particular the advantage of being easy to use in a medical or veterinary context, for example in a hospital or clinic.

10 The subject of the present invention is an *in vitro* method of documenting a repertoire of (an) NKR immunoreceptor(s) comprising in particular the KIR p58.1, p58.2, p70.INH and p140.INH, and the NKG2A and NKG2B receptors, and/or of a repertoire of (an) NKR
15 immunoreceptor counterpart(s), comprising in particular the KAR p50.1, p50.2, p70.ACT and p140.ACT receptors, and the NKG2C, NKG2D, NKG2E and NKG2F receptors, these immunoreceptors being designated hereinafter target receptor(s), characterized in that it comprises:
20 i. the use of at least one pair of oligonucleotides, one being designated 3' oligonucleotide and the other 5' oligonucleotide, the 3' and 5' oligonucleotides of the same said pair both being capable, under hybridization conditions corresponding to incubation
25 for 1 min in a buffer [20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl₂] at a temperature of between 50°C and 65°C approximately, of hybridizing to the DNA or to the cDNA of a target NKR receptor, or NKR counterpart, but not hybridizing, under the same hybridization
30 conditions, with the DNA or the cDNA of an NKR receptor counterpart, or respectively of an NKR receptor, functional counterpart of the said target receptor,
ii. the bringing of DNA or cDNA populations of a biological sample of human or animal origin for which
35 it is desired to document the repertoire of target immunoreceptor(s), into contact with an excess of at least one 3' and 5' oligonucleotide pair according to i. under conditions favourable to the hybridization of

this 3' and 5' oligonucleotide pair with the DNAs or cDNAs of the biological sample, and

iii. the detection of the possible hybrids formed between these DNAs or cDNAs and the 3' and 5' oligonucleotide pair(s).

Functional counterpart of a receptor is understood to mean in the present application a receptor with a homologous structure, in particular at the extracytoplasmic level, but with a different function: for example, a functional counterpart of the NKR p58.1 receptor is the NKR p50.1 receptor counterpart, and conversely; likewise the NKR p58.2 receptor and the NKR p50.2 receptor counterpart are functional counterparts for one another.

The present method therefore makes it possible in particular to distinguish an NKR receptor (or NKR counterpart) from a functional receptor counterpart of this receptor.

The 3' and 5' oligonucleotide pair(s) is (are) in particular capable of delimiting, on the DNA or the cDNA of a target receptor corresponding thereto, an oligonucleotide sequence (limits included) which is absent from the DNA or cDNA sequence of a receptor with which it (they) is (are) capable of not hybridizing under the hybridization conditions given under i) above.

Advantageously, the said or at least one of the said 3' and 5' oligonucleotide pair(s) used is in addition capable, under the same hybridization conditions as those defined under i., of not hybridizing to the DNA or cDNA of a receptor, either NKR or NKR counterpart, other than the said target receptor.

According to a particular arrangement of this advantageous manner, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) capable, under the hybridization conditions defined under i. above, of hybridizing to the DNA or the cDNA of a p58.1 (or p50.1) receptor, and of not hybridizing to the DNA or

the cDNA of a p50.1 receptor (or respectively p58.1) is in addition capable of not hybridizing under the same hybridization conditions to the DNA or the cDNA of a p58.2 or p50.2 receptor.

5 According to a second particular arrangement of this advantageous manner, the said, or at least one of the said, 3' and 5' oligonucleotide pair(s) capable, under the hybridization conditions defined under i. above, of hybridizing to the DNA or the cDNA of a p58.2
10 (or p50.2) receptor, and of not hybridizing to the DNA or the cDNA of a p50.2 (or respectively p58.2) receptor is in addition capable of not hybridizing under the same hybridization conditions to the DNA or the cDNA of a p58.1 or p50.1 receptor.

15 According to a third particular arrangement of this advantageous manner, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) capable, under the hybridization conditions defined under i. above, of hybridizing to the DNA or the cDNA of a
20 p70.INH (or p70.ACT) receptor, and of not hybridizing to the DNA or the cDNA of a p70.ACT (or respectively p70.INH) receptor is in addition capable of not hybridizing under the same hybridization conditions to the DNA or the cDNA of a p140.INH or p140.ACT receptor.

25 According to a fourth particular arrangement of this advantageous manner, the said, or at least one of the said, 3' and 5' oligonucleotide pair(s) capable, under the hybridization conditions defined under i. above, of hybridizing to the DNA or the cDNA of a
30 p140.INH (or p140.ACT) receptor, and of not hybridizing to the DNA or the cDNA of a p140.ACT (or respectively p140.INH) receptor is in addition capable of not hybridizing under the same hybridization conditions to the DNA or the cDNA of a p70.INH or p70.ACT receptor.

35 According to an advantageous embodiment of the invention, the 5' oligonucleotide of a said 3' and 5' oligonucleotide pair used for an NKR target receptor (or NKR counterpart) is capable, under the hybridization conditions defined under i. above, of

hybridizing to the DNA or to the cDNA of an NKR receptor counterpart (or respectively NKR receptor), functional counterpart of the said NKR target receptor (or respectively NKR receptor counterpart). According to an advantageous arrangement of this embodiment, the 5' oligonucleotide sequence of a said 3' and 5' oligonucleotide pair used for an NKR target (or NKR counterpart) receptor comprises the 5' oligonucleotide sequence of another said 3' and 5' oligonucleotide pair having as target receptor an NKR receptor counterpart (or respectively NKR receptor), functional counterpart of the said NKR target receptor (or respectively NKR receptor counterpart).

According to another advantageous embodiment of the invention, the 3' oligonucleotide of a said 3' and 5' oligonucleotide pair, used for a KAR target receptor, is capable, under the same said hybridization conditions, of hybridizing to the DNA or cDNA of the said KAR target receptor at the level of a nucleotide stretch which comprises a sequence corresponding, according to the universal genetic code, and taking into account the degeneracy of the said code, to the amino acid sequence Lys Ile Pro Phe Thr Ile (K I P F T I) or Lys Leu Pro Phe Thr Ile (K L P F T I) (SEQ ID No. 26 or 27).

According to a particularly advantageous embodiment of the invention, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a KIR receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of: a 5' oligonucleotide comprising the sequence SEQ ID No. 1, or a sequence which is derived therefrom, and at least one 3' oligonucleotide comprising the sequence SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom, a 5' oligonucleotide comprising the sequence SEQ ID No. 4, or a sequence which is derived therefrom, and at least one 3' oligonucleotide comprising the sequence

SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom,

a 5' oligonucleotide comprising the sequence SEQ ID No. 9, or a sequence which is derived therefrom, and at

5 least one 3' oligonucleotide comprising the sequence SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom,

at least one 5' oligonucleotide comprising the sequence SEQ ID No. 10, No. 11, No. 12 or No. 13, or a sequence

10 which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 14, or a sequence which is derived therefrom.

Sequence which is derived from a first sequence is understood to mean in the present application a
15 sequence derived from the first in particular by inversion, deletion, addition or substitution of nucleotide(s), and exhibiting the hybridization properties which the nucleic acid corresponding to the first sequence exhibits under the conditions i. defined
20 above.

According to one arrangement of this particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p58.1 receptor corresponds to a 5' oligonucleotide
25 comprising SEQ ID No. 1, or a sequence which is derived therefrom, and an equal mixture of four 3' oligonucleotides, each of them comprising SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom.

30 According to another arrangement of this particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p58.2 receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 4, or a sequence which is derived
35 therefrom, and an equal mixture of four 3' oligonucleotides, each of them comprising SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom.

According to yet another arrangement of this particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p70.INH receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 9, or a sequence which is derived therefrom, and an equal mixture of four 3' oligonucleotides, each of them comprising SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom.

According to yet another arrangement of this particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p140.INH receptor corresponds to an equal mixture of four 5' oligonucleotides, each of them comprising SEQ ID No. 10, No. 11, No. 12 or No. 13, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 14, or a sequence which is derived therefrom.

According to another particularly advantageous embodiment of the invention, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a KAR receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of:

- a 5' oligonucleotide comprising the sequence SEQ ID No. 1, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,
- a 5' oligonucleotide comprising the sequence SEQ ID No. 8, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,
- a 5' oligonucleotide comprising the sequence SEQ ID No. 9, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,
- a 5' oligonucleotide comprising the sequence SEQ ID No. 15, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom.

According to one arrangement of this other particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p50.1 receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 1, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 3, or a sequence which is derived therefrom.

According to another arrangement of this other particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p50.2 receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 8, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 3, or a sequence which is derived therefrom.

According to yet another arrangement of this other particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p70.ACT receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 9, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 3, or a sequence which is derived therefrom.

According to yet another arrangement of this other particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p140.ACT receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 15, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 3, or a sequence which is derived therefrom.

According to yet another particularly advantageous embodiment of the invention, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a NKG2 receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of:

- a 5' oligonucleotide comprising the sequence SEQ ID No. 16, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 18, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 19, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 20, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 21, or a sequence which is derived therefrom.

According to a first arrangement of this yet another particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor an NKG2A (inhibitor) receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 16, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 17, or a sequence which is derived therefrom.

According to a second arrangement of this yet another particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor an NKG2B (inhibitor) receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 18, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 17, or a sequence which is derived therefrom.

According to a third arrangement of this yet another particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor an NKG2C (activator) receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 19, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 17, or a sequence which is derived therefrom.

According to a fourth arrangement of this yet another particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor an NKG2D (activator) receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 20, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 21, or a sequence which is derived therefrom.

The said conditions which are favourable for the hybridization of the 3' and 5' oligonucleotide pair(s) brought into contact with the DNA or the cDNA of the biological sample advantageously correspond to an incubation for 1 min in a buffer [20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl₂] at a temperature of between 50°C and 65°C approximately. Such conditions are in particular presented in the examples.

Advantageously, the two 3' or 5' oligonucleotides of the same said pair are each coupled to a marker, in particular coupled to a fluorescent or radioactive marker, such as ³²P, allowing the visualization of the hybrids which they may form with the said DNA or cDNA populations of the said biological sample.

In an equally advantageous manner, the said 3' and 5' oligonucleotide pair(s) serve(s) as 3' and 5' primers, respectively, for extension by DNA polymerase, such as a Taq polymerase. Conditions which are favourable for such an extension comprise, apart from the addition of DNA polymerase, the addition of the 4 dNTPs (deoxyribonucleoside triphosphates) in the presence of a Tris-HCl-type buffer.

The said hybrids which may be formed are then, prior to their detection, amplified by at least one PCR (amplification by the polymerase chain reaction; cf. patents EP 201,184 and EP 200,362) or RT-PCR in the case of cDNA retrotranscribed from mRNA. Where appropriate, the said hybrids which may be formed are amplified by nested PCR. Examples of conditions which

are favourable for the PCR amplification are given in the examples.

According to another advantageous embodiment of the invention, the said detection of the hybrids which
5 may be formed comprises, in addition, the resolution, on a polyacrylamide gel, of the reaction mixture derived from the bringing into contact, as well as the visualization of the presence or of the absence of electrophoretic bands containing the said hybrids which
10 may be formed.

According to another embodiment of the invention, the documented immunoreceptor repertoire is quantified with reference to the quantities of β -actin measured in the same biological sample, or with
15 reference to the quantities of a specific molecule of a cellular type which are present in the said biological sample, such as in particular the CD56 molecules for the NK cells.

The method according to the invention may be
20 applied to the documentation of a genotypic repertoire of NKR immunoreceptors and/or of NKR immunoreceptor counterparts: step ii. of the bringing into contact defined above is then carried out with the genomic DNA populations of the biological sample.

The method according to the invention may also
25 be applied to the documentation of an expression repertoire of NKR immunoreceptors and/or of NKR immunoreceptor counterparts: step ii. of the bringing into contact defined above is then carried out with the
30 cDNA populations retrotranscribed from the mRNA populations of the biological sample.

Biological samples of human or animal origin which are particularly appropriate for carrying out the method according to the invention comprise peripheral
35 blood, bone marrow, lymphocytes, NK and/or T cells, transgenic cells expressing immunoreceptors and a fraction isolated from these samples.

The method according to the invention may be applied in particular to the screening of a library of organs, tissues or cells.

It thus allows better prediction:

- 5 - of the acceptance or rejection, by a human or an animal, of cells, of a tissue or of an organ which is (are) genetically different,
- of the safety or pathogenicity (GVH effect), for a human or an animal, of a graft or transplant, in
10 particular of cells, tissue or organ which is (are) genetically different,
- of a potential effect of the GVL type which cells, a tissue or an organ which is (are) genetically different could exert on a human or an animal.

15 The method according to the invention also allows the monitoring of the possible appearance of such reactions after allo- or xeno-genic grafting or transplantation.

20 The method according to the invention can also be applied to the determination of the state of activation of NK and/or T cells at a given instant in an animal or a human. It allows, in this case, the prediction or monitoring of the state of resistance of an animal or a human towards a viral infection, such as
25 an HIV infection, or a parasitic infection, such as malaria, or a bacterial infection, towards an autoimmune disease, such as rheumatoid arthritis, or alternatively towards the development of malignant cells such as leukaemia cells. The predictive use of
30 the method according to the invention is of particular importance in the context of epidemics.

35 The method according to the invention can also be advantageously applied to the screening of medicaments which are active on infectious diseases, on autoimmune diseases and on tumour diseases.

 The subject of the present invention is also a kit for carrying out the said method comprising, in a container, at least one said oligonucleotide pair, the reagents for carrying out the said method(s) such as a

buffer, a marker (optionally coupled to the oligonucleotides of the said pair), as well as instructions for use.

5 Other characteristics and advantages of the present invention will further emerge from the following exemplary embodiments which are given as a guide and without limitation.

The said examples refer to Figures 1 and 2:

10 Figure 1 represents the products derived from a PCR amplification (amplification by the polymerase chain reaction after enzymatic reverse transcription, RT, with the aid of oligonucleotide pairs according to the invention serving as primers), of the sequences encoding p50.2 (Fig. 1A) and p58.2 (Fig. 1B) in human
15 NK cells;

Figure 2 represents the products derived from a PCR amplification of the sequence encoding p50.2 from the genomic DNA of p50.2⁺ transgenic mice.

Example 1: Documentation of the NKR/NKR counterpart
20 repertoire expressed by a population of human NK cells (RT-PCR).

1. Preparation of the RNAs

RNA preparations were made from cloned human NK cells phenotyped p50.2⁺ and/or p58.2⁺. Immunological
25 technique does not make it possible to accurately document such a repertoire: the antibody GL183 (Immunotech) recognizes both the inhibitory NKR receptor p58.2 and its activatory counterpart p50.2. Cloned human NK cells phenotyped p50.2⁻ and p58.2⁻ with
30 the aid of the antibody GL183 serve as negative controls.

The RNA preparations are made as follows.

Extraction

35 100 µl of Trizol (Gibco BRL category No. 15596-026) were added to 10⁶ cells. The medium is mixed by pipetting several times, without using a vortex mixer. The solution is left for 5 minutes at room temperature and then 20 µl of chloroform, free of isoamyl alcohol, are added. The medium is again mixed without using a

vortex mixer and the solution is allowed to stand for 5 minutes at room temperature. It is then centrifuged at 4°C for 15 minutes so as to properly separate the bottom organic phase, which contains the DNA, from the top aqueous phase which contains the RNA. The aqueous phase is recovered without disturbing the interface between the aqueous phase and the organic phase.

Precipitation

50 µl of isopropanol are added to the aqueous phase and the RNA is allowed to precipitate for 15 minutes at room temperature. The medium is then centrifuged for 10 minutes at 4°C. The supernatant is removed, and the pellet is washed with 100 µl of 70% ethanol. After centrifuging for 5 minutes at 4°C (7500 g), the medium is allowed to dry in the open air (without drying under vacuum). The RNA pellet is resuspended in 20 ml of H₂O.

2. Preparation of the oligonucleotide pairs

Table 1 below presents the oligonucleotide pairs used. Reported here are the results relating to the use of the oligonucleotide pairs C (SEQ ID No. 4 as 5' oligonucleotide and an equal mixture of SEQ ID No. 5, No. 2, No. 6 and No. 7 as 3' oligonucleotide) and D (SEQ ID No. 8 as 5' oligonucleotide and SEQ ID No. 3 as 3' oligonucleotide) which are presented in Table 1. The cDNA sequences, on the basis of which these oligonucleotide pairs were developed, are presented in Table 2 below (name of the cDNA clones and Genbank accession number). For each oligonucleotide pair, the allelic variants and the excision-splicing variants (alternative splicing) known for the same receptor were thus taken into account.

Each oligonucleotide pair is constructed, after alignment of the known cDNA sequences of the different variants of the same target receptor (e.g. KIR p58.2), so that this pair can determine, on all these variants, the limits of a consensus fragment, without being able, as a result, to do likewise on any variant of the receptor counterpart of the target receptor (e.g. KAR

p50.2). The sequence of each oligonucleotide of the same pair is then optimized so that the annealing temperature for each of them is similar (e.g. $\Delta T \leq 5^{\circ}\text{C}$).

5 Each oligonucleotide indeed has an annealing temperature which is specific to it. This annealing temperature depends on the ratio

$$10 \quad R = \frac{G + C}{\text{total number of bases}} \times 100 \quad \text{and on the}$$

length of the oligonucleotide considered, according to the formula: annealing temperature of an
15 oligonucleotide =

$$T_m = 69.3 + 0.41(R) - \frac{650}{\text{length in bp}} \quad (\text{in } ^{\circ}\text{C})$$

20

However, in a reaction of the polymerase chain reaction type, the oligonucleotides of the same pair should both be able to anneal to the target receptor under common reaction conditions, this being so as to
25 serve as primers for the amplification of the consensus fragment. If the oligonucleotides of the same pair have similar specific annealing temperatures (e.g. 54°C and 56°C), they will be able to hybridize to the target receptor, without, as a result, hybridizing to the
30 corresponding receptor counterpart, at a temperature of 54°C or 55°C .

If the oligonucleotides of the same pair have, on the other hand, very different specific annealing temperatures (e.g. 49°C and 56°C), the reaction for
35 hybridizing to the target receptor is preferably carried out at the lower of the two temperatures (e.g. 49°C or 50°C), which makes it possible to maintain the recognition of its nucleotide target by the oligonucleotide whose specific annealing temperature is

the lowest. In this situation, a decrease in specificity can however occur: it is possible to observe that some oligonucleotide pairs succeed, under such temperature conditions, in hybridizing to the target receptor counterpart-receptor. A way of counteracting this loss of specificity consists in increasing the length of the oligonucleotide whose specific annealing temperature is the lowest, without causing the oligonucleotide pair considered to lose its specificity.

3. Amplification by the polymerase chain reaction after enzymatic reverse transcription (RT-PCR)

5 μ g of total RNA are transcribed into cDNA by incubating with a reverse transcriptase (RT) with the aid of the First Strand DNA-Ready to go kit (Pharmacia). 10 μ l of cDNA out of the 33 μ l obtained are brought into contact with oligonucleotide pairs C and D which serve, in this case, as primers (cf. Table 1): 10 μ l of RT-derived product; 10X PCR buffer: 10 μ l; $MgCl_2$ 50 mM; dXTP 10 mM; 3' oligonucleotide at 10 μ M: 5 μ l; 5' oligonucleotide 10 μ M: 5 μ l; Taq polymerase: 0.5 μ l; H_2O : qs 100 μ l. The PCR amplification (DNA engine PTC 200, MJ Research, Massachusetts) is carried out according to the following steps:

- step No. 1 (initial denaturation): 5 min at 94°C,
- step No. 2: 35 cycles comprising
 - a) denaturation 1 min at 94°C
 - 30 b) annealing 1 min at 55°C for the oligonucleotide pair C and 50°C for the oligonucleotide pair D,
 - c) extension 1 min at 72°C,
- step No. 3: (final extension):
35 1 min at 72°C.

The duration of extension 2c can be increased if the fragment to be amplified is of a large size (e.g. greater than 1000-1400 bp approximately).

The temperature in the annealing step 2b depends on the pair of oligonucleotides used as primers (cf. point 2. above). It corresponds to a consensus temperature between the annealing temperatures specific for each of the two oligonucleotides forming a pair (mean temperature or the lower of the two temperatures). This temperature is generally between 45°C and 70°C, preferably between 50°C and 65°C.

10 10 µl of the products derived from the amplification by RT-PCR are resolved by electrophoresis on a 2% agarose gel in parallel with molecular weight markers (M).

The results are illustrated in Figures 1A and 1B.

15 Figure 1 illustrates the PCR amplification after RT (enzymatic reverse transcription) of the sequences encoding p58.2 and p50.2 of human NK cells.

In Figure 1A is illustrated the result of the electrophoretic resolution of the products derived from the RT-PCR amplification after bringing the pair of primers D according to the invention (cf. Table 1) into contact with the cDNA populations of human NK cells phenotyped p50.2⁺ and p58.2⁺ (lane +) with the aid of the antibody GL183, or with the cDNA populations of human NK cells phenotyped p50.2⁻ and p58.2⁻ (lane -) with the aid of this same antibody GL183. The molecular weight markers are resolved in lane M.

30 In Figure 1B is illustrated the result of the electrophoretic resolution of the products derived from the RT-PCR amplification after bringing the pair of primers C according to the invention (cf. Table 1) into contact with the cDNA populations of human NK cells phenotyped p50.2⁺ and p58.2⁺ (lane +) with the aid of the antibody GL183, or with the cDNA populations of human NK cells phenotyped p50.2⁻ and p58.2⁻ (lane -) with the aid of this same antibody GL183. The molecular weight markers are resolved in lane M.

35 It can be observed that the pairs of oligonucleotides C and D according to the invention

make it possible to recognize respectively a phenotype, respectively, p58.2⁺ and p50.2⁺, by recognizing a fragment of, respectively, 653 bp and 533 bp. The method according to the invention therefore makes it possible to discriminate between a p58.2⁺ phenotype (KIR receptor, with inhibitory function) and a p50.2⁺ phenotype (KAR receptor counterpart of p58.2, with activatory function), which up until now could not be carried out by sequencing.

10 Example 2: Documentation of the NKR/NKR counterpart (potential) genetic repertoire of a population of p50.2⁺ transgenic mouse splenocytes (PCR).

1 - Preparation of the DNAs

DNA preparations were carried out using p50.2⁺ transgenic mouse splenocytes. Immunological technique does not make it possible to determine if such splenocytes are p50.2⁺ (KAR receptor, activatory) or p58.2⁺ (KIR receptor, inhibitory, or alternatively p50.2⁺ and p58.2⁺). Non-transgenic mouse splenocytes (p50.2⁻) serve as negative controls.

Extraction

This step is carried out as described in Example 1. The DNAs being contained in the bottom organic phase, it is this phase which is recovered here after having removed the aqueous phase and a small amount of interface.

Precipitation

30 µl of 100% ethanol are added and the medium is allowed to stand for 5 minutes at room temperature. After centrifuging for 5 minutes at 4°C (2000 g), the supernatant is discarded and the pellet is washed with 100 µl of 0.1 M sodium citrate in 10% ethanol. The medium is left for 30 minutes at room temperature while mixing from time to time. It is centrifuged for 5 minutes at 4°C (2000 g). This washing is repeated a second time.

The DNA pellet obtained is resuspended in 200 µl of 70% ethanol. The medium is left for 15

minutes at room temperature while mixing from time to time and centrifuged for 5 minutes at 4°C (2000 g).

The pellet is left to dry briefly under vacuum (1 to 2 µg of DNA approximately are obtained) and is resuspended in 10 µl of 8 mM NaOH. If insoluble material is present, the medium is microcentrifuged for 10 minutes at room temperature. The supernatant is transferred into a new tube. The pH is neutralized by adding 1.25 µl of 0.1 M Hepes per 10 µl.

10 2 - Preparation of the oligonucleotide pairs

The oligonucleotide pairs are prepared as described in Example 1. Reported here are the results relating to the oligonucleotide pair D (SEQ ID No. 8 as 5' oligonucleotide and SEQ ID No. 3 as 3' oligonucleotide) according to the invention (cf. Table 1 below).

3 - Amplification by the polymerase chain reaction (PCR)

Amplification by the polymerase chain reaction is carried out as described in Example 1 by bringing the genomic DNA preparations obtained into contact with oligonucleotide pairs D which serve, in this case, as primers.

The products derived from the amplification are resolved on 2% agarose gel in parallel with molecular weight markers (M).

The results of electrophoretic resolution on 2% agarose gel of the PCR-derived products are illustrated by Figure 2.

Figure 2 illustrates the PCR amplification of the sequence encoding p50.2 from the genomic DNA of p50.2⁺ transgenic mouse splenocytes: illustrated therein is the result of the electrophoretic resolution of the products derived from PCR amplification after bringing the pair of primers D according to the invention (cf. Table 1) into contact with the DNA populations of splenocytes of p50.2⁺ transgenic mice (lanes +) or of p50.2⁻ non-transgenic mice (lanes -). The molecular weight markers are resolved in lane M.

The D primers according to the invention make it possible to recognize a fragment of 533 bp present on the DNA of p50.2⁺ murine splenocytes and absent from the DNA of p50.2⁻ murine splenocytes.

5 Similar results were obtained with the oligonucleotide pairs A, B and E to L presented in Table 1 below and also made it possible to document the desired receptors (cf. "molecule" column of Table 1).

10 The NKR and/or NKR counterpart repertoires thus documented can be, in particular with the aid of conventional biostatic studies, correlated with given physiological or pathological situations linked to these repertoires, and with the control of the activation of the cells expressing them in general.

TABLE 1

Oligo pair	Molecule	Function	Tm	Name of oligo	Sequence of the oligo (5'-->3')	Oligo 5' sequence Oligo 3'
A	p58.EB6 (p58.1)	Inhibitory	56°C 54°C	p58.1FOR ITIM N-term BACK	AGTCGCATGACGCCAAGAC CAACTGTG (T/C) (A/G) TATGTCAC	Seq ID NO.1 Seq ID NO.5,2,6,7
B	p50.EB6 (p50.1)	Activatory	56°C 49°C	p58.1 FOR TM-ACT BACK	AGTCGCATGACGCCAAGAC GATGGTGAAAGGGATTTT	Seq ID NO.1 Seq ID NO.3
C	p58.183 (p58.2)	Inhibitory	56°C 54°C	p58.2 FOR ITIM N-term BACK	GGTCCCATGATGCAAGAC CAACTGTG (T/C) (A/G) TATGTCAC	Seq ID NO.4 Seq ID NO.5,2,6,7.
D	p50.183 (p50.2)	Activatory	56°C 49°C	p58.2 FOR TM-ACT BACK	GGTCCCATGATGCAAGAC GATGGTGAAAGGGATTTT	Seq ID NO.8 Seq ID NO.3

TABLE 1 (continued)

E	p70.INH	Inhibitory	58°C 54°C	p70.FRO ITIM N-term BACK	CCCCGTGGTGATCATGGTC CAACTGTG(T/C)(A/G)TATGTCAC	Seq ID NO.9 Seq ID NO.5,2,6,7.
F	p70.ACT	Activatory	58°C 49°C	p70.FOR TM-ACT BACK	CCCCGTGGTGATCATGGTC GATGGTGAAAGGATTTT	Seq ID NO.9 Seq ID NO.3
G	p140.INH	Inhibitory	56°C 58°C	ITIM N-term.FOR Ext C-term BACK	GTGAC(A/G)TAC(A/G)CACAGTTG ACCTGACTGTGGTGCTCG	Seq ID NO.10,11,12,13 Seq ID NO.14
H	p140.ACT	Activatory	58°C 49°C	p140.FOR TM-ACT BACK	ACCTACAGATGTATGGTCTGT GATGGTGAAAGGATTTT	Seq ID NO.15 Seq ID NO.13
I	NKG2A	Inhibitory	54°C 54°C	NKG2A FOR NKG2A/B/C.BACK	TCTACATTAAATACAGAGGCAC ATCTATAGAAAGCAGACT	Seq ID NO.16 Seq ID NO.17

[illegible]

J	NKG2B	Inhibitory	52°C 54°C	NKG2B.FOR NKG2A/B/C.BACK	ATTCCCTCAGTCATTGT ATCTATAGAAGAAGACACT	Seq ID NO.18 Seq ID NO.17
K	NKG2C	Activatory	54°C 54°C	NKG2C.FOR NKG2A/B/C.BACK	AGTAAACAAGAAGAACCTTC ATCTATAGAAGAAGACACT	Seq ID NO.19 Seq ID NO.17
L	NKG2D	Activatory	56°C 58°C	NKG2D.FOR NKG2D.BACK	AGCAAGAAGACCAGATTTA CACAGTCCCTTTGCATGCAGAT	Seq ID NO.20 Seq ID NO.21
M	CD56		51°C 54°C	5' hCD56 3' hCD56	ATCCAGTACACTGATGAC GTCGATGGATGGTGAAGA	Seq ID NO.22 Seq ID NO.23
N	Actine		62°C 64°C	5' Actine 3' Actine	TACCACCTGGCATCGTGATGCACT TCCTTCTGCATCCTGTGGCAAT	Seq ID NO.24 Seq ID NO.25

TABLE 2

Oligonucleotide pair	Name of the cDNA	Genbank accession number
A	c1-42	U24076
	NKAT-I	L41267
	c1-47.11	U24078
B	X98858	X98585
	X98892	X98892
	NKAT-7AA	L76670
	NKAT-9AA	L76672
C	c1-43	U24075
	NKAT-6AA	L76669
	NKAT-2BA	L76663
	c1-6	U24074
	NKAT-2	L41268
	KIR-023GB	U73395
	NKAT-2AB	L76662
D	NKAT-3DA	L76664
	c1-49	U24079
	NKAT-5	L41347
	X89893	X89893
	c1-39	U24077
	NKAT-8	L76671
	NKAT-5DA	L76667

TABLE 2 (continued)

E	X94262	X94262
	NKAT-3	L41269
	NKBI-1	U31416
	NKBI-2	U33328
	KIR-103AS	U71199
	KIR-103AST	U73394
	c1-1.1	X94373
	c1-11	U30274
	c1-2	U30273
F	NKAT-10	L76661
	KIR-123FM	U73396
G	NKAT-4	L41270
	X94374	X94374
	X93595	X93595
	X93596	X93596
	NKAT-4BA	L76666
	NKAT-4AA	L76665
	c1-5	U30272
I	NKG2A	X54867
J	NKG2B	X54868
K	NKG2C	X54869
L	NKG2D	X54870

CLAIMS

1. *In vitro* method of documenting a repertoire of (an) NKR immunoreceptor(s) comprising in particular the KIR p58.1, p58.2, p70.INH and p140.INH, and the NKG2A and NKG2B receptors, and/or of a repertoire of (an) NKR immunoreceptor counterpart(s), comprising in particular the KAR p50.1, p50.2, p70.ACT and p140.ACT receptors, and the NKG2C, NKG2D, NKG2E and NKG2F receptors, these immunoreceptors being designated hereinafter target receptor(s), characterized in that it comprises:
- i. the use of at least one pair of oligonucleotides, one being designated 3' oligonucleotide and the other 5' oligonucleotide, the 3' and 5' oligonucleotides of the same said pair both being capable, under hybridization conditions corresponding to incubation for 1 min in a buffer [20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl₂] at a temperature of between 50°C and 65°C approximately, of hybridizing to the DNA or to the cDNA of a target NKR receptor, or NKR counterpart, but not hybridizing, under the same hybridization conditions, with the DNA or the cDNA of an NKR receptor counterpart, or respectively of an NKR receptor, functional counterpart of the said target receptor,
 - ii. the bringing of DNA or cDNA populations of a biological sample of human or animal origin for which it is desired to document the repertoire of (a) target immunoreceptor(s), into contact with an excess of at least one 3' and 5' oligonucleotide pair according to
 - i. under conditions favourable to the hybridization of this 3' and 5' oligonucleotide pair with the DNAs or cDNAs of the biological sample, and
 - iii. the detection of the possible hybrids formed between these DNAs or cDNAs and the 3' and 5' oligonucleotide pair(s).
2. Method according to Claim 1, characterized in that the said or at least one of the said 3' and 5' oligonucleotide pair(s) used is in addition capable,

under the same hybridization conditions as those defined under i., of not hybridizing to the DNA or cDNA of a receptor, either NKR or NKR counterpart, other than the said target receptor.

5 3. Method according to any one of the preceding claims, characterized in that the 5' oligonucleotide of a said 3' and 5' oligonucleotide pair used for an NKR target receptor (or NKR counterpart) is capable, under the same said hybridization conditions, of hybridizing
10 to the DNA or to the cDNA of an NKR receptor counterpart (or respectively NKR receptor), functional counterpart of the said NKR target receptor (or respectively NKR receptor counterpart).

15 4. Method according to any one of the preceding claims, characterized in that the 3' oligonucleotide of a said 3' and 5' oligonucleotide pair, used for a KAR target receptor, is capable, under the same said hybridization conditions, of hybridizing to the DNA or cDNA of the said KAR target receptor at the level of a
20 nucleotide stretch which comprises a sequence corresponding, according to the universal genetic code, and taking into account the degeneracy of the said code, to the amino acid sequence Lys Ile Pro Phe Thr Ile (K I P F T I) or Lys Leu Pro Phe Thr Ile (K L P F T
25 I) (SEQ ID No. 26 or 27).

5. Method according to any one of the preceding claims, characterized in that the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a KIR receptor is chosen from the
30 group of 3' and 5' oligonucleotide pairs consisting of: a 5' oligonucleotide comprising the sequence SEQ ID No. 1, or a sequence which is derived therefrom, and at least one 3' oligonucleotide comprising the sequence SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence
35 which is derived therefrom, a 5' oligonucleotide comprising the sequence SEQ ID No. 4, or a sequence which is derived therefrom, and at least one 3' oligonucleotide comprising the sequence

SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom,

a 5' oligonucleotide comprising the sequence SEQ ID No. 9, or a sequence which is derived therefrom, and at

5 least one 3' oligonucleotide comprising the sequence SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom,

at least one 5' oligonucleotide comprising the sequence SEQ ID No. 10, No. 11, No. 12 or No. 13, or a sequence

10 which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 14, or a sequence which is derived therefrom.

6. Method according to any one of the preceding claims, characterized in that the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a KAR receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of:

- a 5' oligonucleotide comprising the sequence SEQ ID No. 1, or a sequence which is derived therefrom, and a

20 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 8, or a sequence which is derived therefrom, and a

25 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 9, or a sequence which is derived therefrom, and a

3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,

30 - a 5' oligonucleotide comprising the sequence SEQ ID No. 15, or a sequence which is derived therefrom, and a

3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom.

7. Method according to any one of the preceding claims, characterized in that the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a NKG2 receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of:

a 5' oligonucleotide comprising the sequence SEQ ID No. 16, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

5 a 5' oligonucleotide comprising the sequence SEQ ID No. 18, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

10 a 5' oligonucleotide comprising the sequence SEQ ID No. 19, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

15 a 5' oligonucleotide comprising the sequence SEQ ID No. 20, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 21, or a sequence which is derived therefrom.

8. Method according to any one of the preceding claims, characterized in that the two 3' or 5' oligonucleotides of the same said pair are each coupled
20 to a marker, in particular coupled to a fluorescent or radioactive marker, such as ³²P, allowing the visualization of the hybrids which they may form with the said DNA or cDNA populations of the said biological sample.

25 9. Method according to any one of the preceding claims, characterized in that the said 3' and 5' oligonucleotide pair(s) serve(s) as 3' and 5' primers, respectively, for extension by DNA polymerase.

30 10. Method according to any one of the preceding claims, characterized in that the said hybrids which may be formed are amplified by at least one PCR prior to their detection.

35 11. Method according to any one of the preceding claims, characterized in that the said hybrids which may be formed are amplified by nested PCR.

12. Method according to any one of the preceding claims, characterized in that the said detection of the hybrids which may be formed comprises, in addition, the

resolution, on a polyacrylamide gel, of the reaction mixture derived from the bringing into contact, as well as the visualization of the presence or of the absence of electrophoretic bands containing the said hybrids which may be formed.

13. Method according to any one of the preceding claims, characterized in that it is applied to the documentation of a genotypic repertoire of NKR immunoreceptors and/or of NKR immunoreceptor counterparts.

14. Method according to any one of the preceding claims, characterized in that it is applied to the documentation of an expression repertoire of NKR immunoreceptors and/or of NKR immunoreceptor counterparts.

15. Method according to any one of the preceding claims, characterized in that the said biological sample of human or animal origin is peripheral blood, bone marrow, lymphocytes, NK and/or T cells, transgenic cells expressing immunoreceptors and a fraction isolated from these samples.

16. Method according to any one of the preceding claims, characterized in that it is applied to the screening of a library of organs, tissues or cells.

17. Method according to any one of the preceding claims, characterized in that it is applied to the prediction or to the monitoring of the acceptance or rejection, by a human or an animal, of cells, tissue or organ which is (are) genetically different.

18. Method according to any one of the preceding claims, characterized in that it is applied to the prediction or to the monitoring of the safety or of the pathogenicity (GVH), for a human or an animal, of a graft or transplant, of cells, tissue or organ which is (are) genetically different.

19. Method according to any one of the preceding claims, characterized in that it is applied to the prediction or to the monitoring, for a human or an

animal, of a GVL-type effect on the part of cells, tissue or organ which is (are) genetically different.

20. Method according to any one of the preceding claims, characterized in that it is applied to the
5 determination of the state of activation of NK and/or T cells at a given instant in an animal or a human.

21. Method according to any one of the preceding claims, characterized in that it is applied to the prediction or to the monitoring of the state of
10 resistance of an animal or a human towards a viral infection, such as an HIV infection, or a parasitic infection, such as malaria, or a bacterial infection, towards an autoimmune disease, such as rheumatoid arthritis, or alternatively towards the development of
15 malignant cells such as leukaemia cells.

22. Method according to any one of the preceding claims, characterized in that it is applied to the screening of medicaments which are active on infectious diseases, on autoimmune diseases and on tumour
20 diseases.

23. Kit for carrying out the method according to any one of Claims 1 to 22, characterized in that it comprises, in a container, at least one said 3' and 5' oligonucleotide pair, the reagents for carrying out the
25 said method(s) such as a buffer, a marker (optionally coupled to the oligonucleotides of the said pair), as well as instructions for use.

SEQUENCE LISTING

(1) GENERAL INFORMATION

5

(i) APPLICANT:

- (A) NAME: I. N. S. E. R. M
- (B) STREET: 101 rue de Tolbiac
- (C) CITY: PARIS
- (E) COUNTRY: FRANCE
- (F) POSTAL CODE: 75654

10

(ii) TITLE OF INVENTION: Method of documenting NKR immunoreceptors and NKR immunoreceptor counterparts

15

(iii) NUMBER OF SEQUENCES: 27

(iv) COMPUTER READABLE FORM

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

20

25 (2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleotide
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: Other nucleic acid

35

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: p58.1 FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

REPLACEMENT PAGE (RULE 26)

AGTCGCATGA CCCAAGAC

18

(3) INFORMATION FOR SEQ ID NO: 2:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

10

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

15

(C) INDIVIDUAL/ISOLATE: ITIM N-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CAACTGTGTG TATGTCAC

18

20

(4) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

25

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

30

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: TM-ACT BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

35

GATGGTGAAA GGGATTTT

18

(5) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleotide
5 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid
(vi) ORIGINAL SOURCE:
10 (C) INDIVIDUAL/ISOLATE: p58.2 FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GGTCCCATGA TGCAAGAC 18

15 (6) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
20 (B) TYPE: nucleotide
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid
25 (vi) ORIGINAL SOURCE:
 (C) INDIVIDUAL/ISOLATE: ITIM N-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
30 CAACTGTGTA TATGTCAC 18

(7) INFORMATION FOR SEQ ID NO: 6:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleotide
 (C) STRANDEDNESS: single

REPLACEMENT PAGE (RULE 26)

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

5 (C) INDIVIDUAL/ISOLATE: ITIM N-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CAACTGTGCA TATGTCAC

18

10

(8) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

15

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

20

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: ITIM N-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

25

CAACTGTGCG TATGTCAC

18

(9) INFORMATION FOR SEQ ID NO: 8:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: p58.2 FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

5 GGTCCCATGA TGCAAGAC 18

(10) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 18 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: p70.FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

20 CCCGTGGTGA TCATGGTC 18

(11) INFORMATION FOR SEQ ID NO: 10:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: ITIM N-term. FOR

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GTGACATACA CACAGTTG 18

(12) INFORMATION FOR SEQ ID NO: 11:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Other nucleic acid
10 (vi) ORIGINAL SOURCE:
(C) INDIVIDUAL/ISOLATE: ITIM N-term. FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
15 GTGACATACG CACAGTTG 18

(13) INFORMATION FOR SEQ ID NO: 12:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: Other nucleic acid
(vi) ORIGINAL SOURCE:
(C) INDIVIDUAL/ISOLATE: ITIM N-term. FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
30 GTGACGTACA CACAGTTG 18

(14) INFORMATION FOR SEQ ID NO: 13:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleotide
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

5 (C) INDIVIDUAL/ISOLATE: ITIM N-term. FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GTGACGTACG CACAGTTG 18

10

(15) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

15

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

20

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: Ext C-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

25

ACCTGACTGT CGTGCTCG 18

(16) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 24 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: p140.FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

ACCTACAGAT GTTATGGTTC TGTT 24

5 (17) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleotide

10 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

15 (C) INDIVIDUAL/ISOLATE: NKG2A.FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

TCTACATTAA TACAGAGGCA C 21

20 (18) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

25 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

30 (C) INDIVIDUAL/ISOLATE: NKG2A/B/C. BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

ATCTATAGAA AGCAGACT 18

35

(19) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleotide
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5

- (ii) MOLECULE TYPE: Other nucleic acid
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL/ISOLATE: NKG2 B FOR

10

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

ATTCCCTCAC GTCATTGT

18

- (20) INFORMATION FOR SEQ ID NO: 19:

15

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

20

- (ii) MOLECULE TYPE: Other nucleic acid
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL/ISOLATE: NKG2C. FOR

25

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AGTAAACAAA GAGGAACCTT C

21

30

- (21) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

35

- (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: NKG2D. FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

5

AGCAAAGAGG ACCAGGATT A 21

(22) INFORMATION FOR SEQ ID NO: 21:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: NKG2D. BACK

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

CACAGTCCTT TGCATGCAGA T 21

(23) INFORMATION FOR SEQ ID NO: 22:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: 5' hCD56

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

ATCCACTACA CTGATGAC 18

(24) INFORMATION FOR SEQ ID NO: 23:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: 3' hCD56

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GTCGATGGAT GGTGAAGA

18

(25) INFORMATION FOR SEQ ID NO: 24:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: 5' Actin

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

TACCACTGGC ATCGTGATGG ACT

23

(26) INFORMATION FOR SEQ ID NO: 25:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid
5 (vi) ORIGINAL SOURCE:
(C) INDIVIDUAL/ISOLATE: 3' Actin

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

10 TCCTTCTGCA TCCTGTCGGC AAT 23

(27) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE:

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26

Lys Ile Pro Phe Thr Ile

1 5

30

(28) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
35 (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(vi) ORIGINAL SOURCE:

5 (C) INDIVIDUAL/ISOLATE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27

Lys Leu Pro Phe Thr Ile

10 1 5

ABSTRACT OF THE INVENTION

The invention relates to an *in vitro* method for documenting a repertoire in NKR immunoreceptors and/or NKR counterparts, consisting of (i) using at least a pair of oligonucleotides 3' and 5' capable of hybridizing with a target NKR receptor, or NKR counterpart, and not capable of being hybridized with a functional counterpart of said target receptor; (ii) contacting said pair of oligonucleotides 3' and 5' with the DNA or DNA of a sample under study; and (iii) detecting the ultimately formed hybrids. The invention also concerns the biological applications of said method, in particular for screening banks of organs, tissues and cells for transplant, and kits for its implementation.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
221

FIGURE 1B




FIGURE 1A





FIGURE 1

2/2

FIGURE 2



Declaration and Power of Attorney for Patent Application Déclaration et Pouvoirs pour Demande de Brevet

French Language Declaration

En tant que l'inventeur nommé ci-après, je déclare par le présent acte que

Mon domicile, mon adresse postale et ma nationalité sont ceux figurant ci-dessous à côté de mon nom

Je crois être le premier inventeur original et unique (si un seul nom est mentionné ci-dessous), ou l'un des premiers co-inventeurs originaux (si plusieurs noms sont mentionnés ci-dessous) de l'objet revendiqué, pour lequel une demande de brevet a été déposée concernant l'invention intitulée

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

VIVIER Eric

20bis, Chemin du Boudard

13260 CASSIS FRANCE

VELY Frédéric

Résidence du Vallat -La Farendole-

13260 CASSIS FRANCE

Cette déclaration est du type suivant

original	<input type="checkbox"/>	original
modèle	<input type="checkbox"/>	design
phase nationale du PCT	<input checked="" type="checkbox"/>	national stage of PCT
divisionnaire	<input type="checkbox"/>	divisional
continuation	<input type="checkbox"/>	continuation
continuation en parties (C-I-P)	<input type="checkbox"/>	continuation-in-part (C-I-P)

This declaration is of the following type

et dont la description est fournie ci-joint à moins que la case suivante n'ait été cochée

☒ a été déposée
le 20/10/98
sous le numéro de demande des Etats-Unis ou le
numéro de demande international PCT/FR98/02244
et modifiée le
(le cas échéant)

the specification of which is attached hereto unless the following box is checked:

☐ was filed on
as United States Application Number or PCT
International Application Number
and was amended on
(if applicable).

Je déclare par le présent acte avoir passé en revue et compris le contenu de la description ci-dessus, revendications comprises, telles que modifiées par toute modification dont il aura été fait référence ci-dessus

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above

Je reconnais devoir divulguer toute information pertinente à la brevetabilité, comme défini dans le Titre 37, § 1.56 du Code fédéral des réglementations.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

☐ Conformément aux termes de cette obligation, les informations exigées sont jointes 37 CFR 1.98 aux présentes

☐ In compliance with this duty there is attached an information disclosure statement 37 CFR 1.98.

[Page 1 of 3]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

French Language Declaration

Je revendique par le présent acte avoir la priorité étrangère, en vertu du Titre 35, § 119(a)-(d) ou § 365(b) du Code des États-Unis, sur toute demande étrangère de brevet ou certificat d'inventeur ou, en vertu du Titre 35, § 365(a) du même Code, sur toute demande internationale PCT désignant au moins un pays autre que les États-Unis et figurant ci-dessous et, en cochant la case, j'ai aussi indiqué ci-dessous toute demande étrangère de brevet, tout certificat d'inventeur ou toute demande internationale PCT ayant une date de dépôt précédant celle de la demande à propos de laquelle une priorité est revendiquée.

Prior foreign application(s)

Demande(s) de brevet antérieure(s)

97 13115

FRANCE

(Number)

(Country)

(Numero)

(Pays)

(Number)

(Country)

(Numero)

(Pays)

(Number)

(Country)

(Numero)

(Pays)

Je revendique par le présent acte tout bénéfice, en vertu du Titre 35, § 119(e) du Code des États-Unis, de toute demande de brevet provisoire effectuée aux États-Unis et figurant ci-dessous.

(Application No.)
(N° de demande)(Filing Date)
(Date de dépôt)(Application No.)
(N° de demande)(Filing Date)
(Date de dépôt)

Je revendique par le présent acte tout bénéfice, en vertu du Titre 35, § 120 du Code des États-Unis, de toute demande de brevet effectuée aux États-Unis, ou en vertu du Titre 35, § 365(c) du même Code, de toute demande internationale PCT désignant les États-Unis et figurant ci-dessous et, dans la mesure où l'objet de chacune des revendications de cette demande de brevet n'est pas divulgué dans la demande antérieure américaine ou internationale PCT, en vertu des dispositions du premier paragraphe du Titre 35, § 112 du Code des États-Unis, je reconnais devoir divulguer toute information pertinente à la brevetabilité, comme défini dans le Titre 37, § 1.56 du Code fédéral des réglementations, dont j'ai pu disposer entre la date de dépôt de la demande antérieure et la date de dépôt de la demande nationale ou internationale PCT de la présente demande.

(Application No.)
(N° de demande)(Filing Date)
(Date de dépôt)(Application No.)
(N° de demande)(Filing Date)
(Date de dépôt)

Je déclare par le présent acte que toute déclaration ci-incluse est, à ma connaissance, véridique et que toute déclaration formulée à partir de renseignements ou de suppositions est tenue pour véridique et de plus, que toutes ces déclarations ont été formulées en sachant que toute fausse déclaration volontaire ou son équivalent est passible d'une amende ou d'une incarcération, ou des deux, en vertu de la Section 1001 du Titre 18 du Code des États-Unis, et que de telles déclarations volontairement fausses risquent de compromettre la validité de la demande de brevet ou du brevet délivré à partir de celle-ci.

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) or § 365 (b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below, and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Claimed
Droit de priorité revendiqué(Day/Month/Year Filed)
(Jour/Mois/Année de dépôt)(Day/Month/Year Filed)
(Jour/Mois/Année de dépôt)(Day/Month/Year Filed)
(Jour/Mois/Année de dépôt)

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Filing Date)
(Date de dépôt)(Filing Date)
(Date de dépôt)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Status) (patented, pending, abandoned)
(Statut) (breveté, en cours d'examen, abandonné)(Status) (patented, pending, abandoned)
(Statut) (breveté, en cours d'examen, abandonné)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

French Language Declaration



POUVOIRS En tant que l'inventeur cité, je désigne par la présente l'(les) avocat(s) et/ou agent(s) suivant(s) pour qu'ils poursuive(nt) la procédure de cette demande de brevet et transmettent toute affaire s'y rapportant avec l'Office des brevets et des marques. (mentionner le nom et le numéro d'enregistrement)

POWER OF ATTORNEY. As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number)

Dana M. Raymond, Reg. No. 18,540; Frederick C. Carver, Reg. No. 17,021; Francis J. Hone, Reg. No. 18,662; Joseph D. Garon, Reg. No. 20,420; Arthur S. Tenser, Reg. No. 18,839; Ronald B. Hildreth, Reg. No. 19,498; Thomas R. Nesbitt, Jr., Reg. No. 22,075; Robert Neuner, Reg. No. 24,316; Richard G. Berkley, Reg. No. 25,485; Richard S. Clark, Reg. No. 26,154; Bradley B. Gerst, Reg. No. 27,551; James J. Maune, Reg. No. 26,948; John D. Murrane, Reg. No. 29,836; Henry Tang, Reg. No. 29,705; Robert C. Schenfeld, Reg. No. 31,300; John A. Fogarty, Jr., Reg. No. 22,348; Louis S. Sorell, Reg. No. 32,439; Rochelle K. Seide, Reg. No. 32,300; Gary M. Butter, Reg. No. 33,841; Marta E. Delsignore, Reg. No. 32,689; and Lisa B. Kole, Reg. No. 35,225.

Send Correspondence to
Adresser toute correspondance à
Baker Botts L L P.
30 Rockefeller Plaza
New York, New York 10112-4498
Customer Number 21003


Direct Telephone Calls to
Adresser tout appel téléphonique à
(nom et numéro de téléphone)
Baker Botts L L P.
212-406-2500

Full name of sole or first inventor Nom complet de l'unique ou premier inventeur <u>Eric VIVIER</u>		Full name of second joint inventor, if any Nom complet de second co-inventeur, le cas échéant <u>Frédéric VELY</u>	
Inventor's signature Signature de l'inventeur  Date <u>March 27, 2000</u>		Second inventor's signature Signature du second inventeur  Date <u>March 27, 2000</u>	
Residence Domicile	<u>20bis, Chemin du Boudard</u> <u>13260 CASSIS</u> <u>FRANCE</u> <u>FRX</u>	Residence Domicile	<u>Résidence du Vallat</u> <u>La Farendole</u> <u>13260 CASSIS</u> <u>FRANCE</u> <u>FRX</u>
Citizenship Nationalité	<u>Française (French)</u>	Citizenship Nationalité	<u>Française (French)</u>
Post Office Address Adresse postale	<u>20bis, Chemin du Boudard</u> <u>13260 CASSIS</u> <u>FRANCE</u>	Post Office Address Adresse postale	<u>Résidence du Vallat</u> <u>La Farendole</u> <u>13260 CASSIS</u> <u>FRANCE</u>

(Fournir les mêmes renseignements et la signature de tout co-inventeur supplémentaire)

(Supply similar information and signature for third and subsequent joint inventors.)

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ Scanned copy is best available. Declaration & power of Attorney